Super-resolution ultrasound to distinguish benign from malignant lymph nodes
Official title: Value of Super-resolution Ultrasound Microvascular Imaging in Distinguishing Benign and Malignant Superficial Lymph Nodes: a Prospective Multi-center Study
Run by Peking University Third Hospital · NCT07155954 · Data updated 2026-11-12
This project tries super-resolution ultrasound to see if it can tell whether enlarged lymph nodes are benign or cancerous in adults who are scheduled for lymph node biopsy or surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 779 (estimated) |
| Sponsor | Peking University Third Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | October 23, 2024 |
| Main results expected | October 22, 2027 |
| Study ends | October 22, 2027 |
| Registry record updated | September 4, 2025 |
| Trial ID | NCT07155954 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with superficially enlarged lymph nodes identified on ultrasound who are scheduled for lymph node biopsy, fine needle aspiration, or surgery and who have no contraindication to ultrasound contrast are ideal candidates.
✕Probably not a fit
Patients who are pregnant or lactating, have had prior chemotherapy or radiotherapy, have allergies to contrast agents or egg/milk, or have severe cardiopulmonary conditions are unlikely to participate or benefit from this imaging approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study uses super-resolution ultrasonography (SRUS) and contrast-enhanced ultrasound (CEUS) to image superficial lymph nodes before biopsy or surgery. Investigators will compare blood flow distribution, perfusion indices, CEUS parameters, and blood supply patterns on SRUS between nodes later confirmed as benign or malignant by pathology. Adults with ultrasound-suspected abnormal lymph nodes who are scheduled for puncture, fine needle aspiration, or surgery are eligible, while pregnant people, those with prior chemo/radiation, contrast allergies, or severe cardiopulmonary disease are excluded. Imaging findings will be correlated with histopathology to determine whether SRUS adds diagnostic value over conventional CEUS.
Why it matters
Potential benefit: If successful, SRUS could improve noninvasive differentiation of benign and malignant lymph nodes and help reduce unnecessary biopsies or guide surgical planning.
How similar studies have gone: Contrast-enhanced ultrasound has shown 80–90% diagnostic accuracy for cervical lymph nodes, but applying super-resolution ultrasound to this question is relatively novel and less well studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * (1)suggested abnormal lymph nodes indicated by ultrasonography; (2) Patients scheduled for lymph nodes puncture or fine needle aspiration or surgery; (3) Age greater than or equal to 18 years old. Exclusion Criteria: * (1) Pregnant and lactating women; (2)pathological results not indicating benign or malignant lymph nodes; (3) history of chemotherapy or radiotherapy ; (4) History of allergies to eggs, milk, and ultrasound contrast agents; (5) Patients with acute coronary syndrome, severe pulmonary hypertension, or acute respiratory distress syndrome.
Where it's running
-
Peking University Third Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: li g cui
- Email: cuijuegang@126.com
- Phone: +86 13910627163
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
LB-208: a new oral treatment for adults with advanced solid tumors or lymphoma
This early study tests whether LB-208, taken once daily by mouth, is safe for adults with advanced solid tumors or lymphoma who have exhausted standard treatments.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV
This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.
-
CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma
This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.
-
Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia
This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.
-
Genetics of Blood Cancers in the U.S. population
This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.